Compiled all in one place, read news articles from each of the news categories, about drugs, the pharmaceutical industry, national and international awareness causes, scientific meetings, trending stories and epgonline.org headlines.

Drug News

Added 23 hours ago Drug news

New analysis shows Vascepa is cost effective and offers better outcomes at lower cost for high risk patients with CV Disease .-Amarin Corporation

Amarin Corporation plc announced a summary of results from a patient-level, cost-effectiveness analysis of icosapent ethyl (Vascepa). This comprehensive analysis...

Added 23 hours ago Drug news

ORION-9 phase III trial of inclisiran meets primary endpoints in lowering LDL-C in HeFH patients.- The Medicines Co

The Medicines Company announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase...

Added 23 hours ago Drug news

Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint.- Bayer + Merck Inc.

Bayer announced that the Phase III study VICTORIA (VerICiguaT glObal study in patients with heart failure with Reduced ejectIon frAction)...

Added 1 day ago Drug news

PROTECTOR 1 Phase III study, evaluating RTB 101 for symptomatic respiratory illness did not meet its primary endpoint.- resTORbio, Inc.

resTORbio, Inc.announced that top line data from the PROTECTOR 1 Phase III study, evaluating the safety and efficacy of RTB...

Added 1 day ago Drug news

Novartis PARAGON-HF analyses suggest Entresto benefit beyond HFrEF .

Novartis announced new subgroup analyses from its global Phase III PARAGON-HF study of patients with heart failure with preserved ejection...

Added 1 day ago Drug news

Interim results from EMPRISE phase III trial of Jardiance show reduced risk of heart failure in Type 2 diabetes with CV disease.- Boehringer + Eli Lilly

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows...

Added 1 day ago Drug news

Analysis of phase III TWILIGHT trial for Brilinta showed reduced risk of bleeding in acute coronary syndromes.- AstraZeneca

New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy, from AstraZeneca, reduced the...

Added 1 day ago Drug news

FDA extends PDUFA date for Twirla, a combined hormonal contraceptive patch, to 16 February 2020.- Agile Therapeutics

Agile Therapeutics, Inc. has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for...

Added 2 days ago Drug news

CHMP positive for solriamfetol to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea .- Jazz Pharma

Jazz Pharmaceuticals plc announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a...

Added 2 days ago Drug news

Advisory Committee recommends Vascepa to reduce the risk of cardiovascular events.- Amarin Corpn.

Amarin Corporation plc announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA has voted unanimously (16-0)...

Search all news articles